<?xml version="1.0" encoding="UTF-8"?><rss version="2.0" xmlns:content="http://purl.org/rss/1.0/modules/content/"><channel><title>研发客研究院 | wechat-feeds</title><link>http://MzA5OTQyNjE3NA.favicon.privacyhide.com/favicon.ico</link><description>独立报告、专业分析、深度解读</description><managingEditor> (hellodword)</managingEditor><pubDate>Mon, 08 Mar 2021 13:45:06 +0800</pubDate><image><url>http://MzA5OTQyNjE3NA.favicon.privacyhide.com/favicon.ico</url><title>研发客研究院 | wechat-feeds</title><link>http://MzA5OTQyNjE3NA.favicon.privacyhide.com/favicon.ico</link><width>64</width><height>64</height></image><item><title>将纳米颗粒伪装成DC细胞，激活T细胞干活？ | 前沿</title><link>https://mp.weixin.qq.com/s/W4IQlFWjtBWrHaKPtsw4jQ</link><description></description><content:encoded><![CDATA[将纳米颗粒伪装成DC细胞，激活T细胞干活？ | 前沿]]></content:encoded><pubDate>Mon, 08 Mar 2021 10:20:49 +0800</pubDate></item><item><title>Will China’s Capital Market Get Better in 2021?</title><link>https://mp.weixin.qq.com/s/ivrSaCsxZ-PFbk-2sq7y_Q</link><description></description><content:encoded><![CDATA[Will China’s Capital Market Get Better in 2021?]]></content:encoded><pubDate>Fri, 05 Mar 2021 11:55:27 +0800</pubDate></item><item><title>Plexium：依托DELPhe平台开发单价蛋白降解物 | 前沿</title><link>https://mp.weixin.qq.com/s/xF2pGTwmKYovOYJTU2EScw</link><description></description><content:encoded><![CDATA[Plexium：依托DELPhe平台开发单价蛋白降解物 | 前沿]]></content:encoded><pubDate>Mon, 01 Mar 2021 10:44:53 +0800</pubDate></item><item><title>Ribon：利用BEACON+平台开发NAD+利用酶抑制剂 | 前沿</title><link>https://mp.weixin.qq.com/s/mdXLh04ElxY8WhwvbYO-aw</link><description></description><content:encoded><![CDATA[Ribon：利用BEACON+平台开发NAD+利用酶抑制剂 | 前沿]]></content:encoded><pubDate>Sat, 27 Feb 2021 09:44:12 +0800</pubDate></item><item><title>China NMPA Approved Tracker: Jan 2021</title><link>https://mp.weixin.qq.com/s/Ith0q2HtrIeLDJSq7lg0pg</link><description></description><content:encoded><![CDATA[China NMPA Approved Tracker: Jan 2021]]></content:encoded><pubDate>Fri, 26 Feb 2021 09:18:13 +0800</pubDate></item><item><title>China Licensing Deals Tracker: Jan 2021</title><link>https://mp.weixin.qq.com/s/Kds8Mk3jFdE0Ls-_TZ1hVg</link><description></description><content:encoded><![CDATA[China Licensing Deals Tracker: Jan 2021]]></content:encoded><pubDate>Wed, 24 Feb 2021 12:18:59 +0800</pubDate></item><item><title>Turnstone：溶瘤病毒和TIL双重开发平台 | 前沿</title><link>https://mp.weixin.qq.com/s/Sr5ML4vXZYLRaTx8OkckYg</link><description></description><content:encoded><![CDATA[Turnstone：溶瘤病毒和TIL双重开发平台 | 前沿]]></content:encoded><pubDate>Mon, 22 Feb 2021 08:30:33 +0800</pubDate></item><item><title>第四批集采落幕，给创新药企哪些启示｜观点</title><link>https://mp.weixin.qq.com/s/ChKJbdLxF5ApXnLohecHHw</link><description></description><content:encoded><![CDATA[第四批集采落幕，给创新药企哪些启示｜观点]]></content:encoded><pubDate>Tue, 09 Feb 2021 21:09:32 +0800</pubDate></item><item><title>TScan Therapeutics的TCR-T：从患者肿瘤中识别共享抗原靶点 | 前沿</title><link>https://mp.weixin.qq.com/s/Cf7tIr7aQ7nPWOzVDmgqNw</link><description></description><content:encoded><![CDATA[TScan Therapeutics的TCR-T：从患者肿瘤中识别共享抗原靶点 | 前沿]]></content:encoded><pubDate>Mon, 08 Feb 2021 16:52:46 +0800</pubDate></item><item><title>胶质母细胞瘤研发的痛点与希望｜分析</title><link>https://mp.weixin.qq.com/s/75YC3mkY-H89hhVtdwKXeA</link><description></description><content:encoded><![CDATA[胶质母细胞瘤研发的痛点与希望｜分析]]></content:encoded><pubDate>Fri, 05 Feb 2021 11:01:09 +0800</pubDate></item></channel></rss>